---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-24-000027"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T07:01:53.730207+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics settles shareholder derivative suit; pays up to $950k in fees, adopts governance reforms

## Summary
- Settlement resolves claims that officers misled investors about GeneSight efficacy and study compliance.
- Myriad will adopt new disclosure committee charter, CCO job profiles, and amendments to several board committee charters.
- Plaintiffs' counsel may seek up to $950,000 in attorneys' fees and costs, paid by Myriad or its insurers.
- Court hearing on proposed settlement scheduled for August 6, 2024; defendants deny wrongdoing.
- Governance reforms to remain in effect for at least four years from adoption.

## SEC filing metadata
- accession: 0000899923-24-000027
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992324000027/0000899923-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992324000027/mygn-20240603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-24-000027
- JSON: https://secwatch.observer/filing/0000899923-24-000027.json
- Plain text: https://secwatch.observer/filing/0000899923-24-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.